版本:
中国

BRIEF-UK Drug Tariff rejects current Woulgan application

May 2 Biotec Pharmacon Asa:

* UK Drug Tariff rejects current Woulgan application

* Subsidiary Biotec Betaglucan has received negative feedback from uk drug tariff regarding application for reimbursement

* management are considering if there are grounds for an appeal in line with NHS' own guidelines

* UK Drug Tariff informed co that nhs has decided not to list woulgan because they consider evidence provided to be insufficient to document cost effectiveness Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐